Cyclacel Pharmaceuticals to Delist from Nasdaq

TL;DR

Nasdaq delisting incoming, moving to OTCQB. Bid price issues.

AI Summary

Cyclacel Pharmaceuticals, Inc. filed an 8-K on March 27, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is transitioning its listing from the Nasdaq Capital Market to the OTCQB Venture Market, effective March 28, 2024. This move is due to the company not meeting Nasdaq's minimum bid price requirement.

Why It Matters

This filing indicates a significant downgrade in the company's trading venue, moving from a major exchange to an over-the-counter market, which may impact liquidity and investor perception.

Risk Assessment

Risk Level: high — Delisting from a major exchange like Nasdaq to an OTC market signals significant financial distress and potential challenges in meeting listing requirements.

Key Players & Entities

• Cyclacel Pharmaceuticals, Inc. (company) — Registrant
• Nasdaq Capital Market (company) — Previous Listing Exchange
• OTCQB Venture Market (company) — New Listing Market
• March 28, 2024 (date) — Effective Date of Transfer
• March 27, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital Ma
• $2.5 million — orted stockholders' equity of less than $2.5 million as of December 31, 2023. The Company's
• $607,000 — The Company's stockholders' equity was $607,000 as of December 31, 2023. The Company m

Filing Documents

• tm2410125d1_8k.htm (8-K) — 27KB
• 0001104659-24-040626.txt ( ) — 240KB
• cycc-20240327.xsd (EX-101.SCH) — 3KB
• cycc-20240327_def.xml (EX-101.DEF) — 26KB
• cycc-20240327_lab.xml (EX-101.LAB) — 36KB
• cycc-20240327_pre.xml (EX-101.PRE) — 25KB
• tm2410125d1_8k_htm.xml (XML) — 5KB

01 Notice of Delisting

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 27, 2024, Cyclacel Pharmaceuticals, Inc. (the "Company") received a notice (the "Notice") from the Listing Qualifications Staff ("Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) because the Company reported stockholders' equity of less than $2.5 million as of December 31, 2023. The Company's stockholders' equity was $607,000 as of December 31, 2023. The Company must submit a plan to the Staff no later than May 10, 2024 advising of actions it has taken or will take to regain compliance with Nasdaq Listing Rule 5550(b)(1). If the Staff determines to accept the plan, the Staff can grant the Company an extension of up to 180 calendar days from the date of the Notice to regain compliance. If the Staff does not approve the plan, the Company may appeal that decision to a Nasdaq hearings panel. The Company's management is reviewing its options to address the noncompliance and expects to submit a plan on or before the May 10, 2024 deadline. The Notice has no immediate effect on the Company's Nasdaq listing, and its common stock will continue to be listed under the symbol "CYCC." However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule 5550(b)(1), then the common stock will be subject to delisting from Nasdaq.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYCLACEL PHARMACEUTICALS, INC. By: /s/ Paul McBarron Name: Paul McBarron Title: Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer Date: March 28, 2024

View Full Filing

View this 8-K filing on SEC EDGAR